Rating Rationale
July 10, 2020 | Mumbai
UPL Limited
Ratings Reaffirmed
 
Rating Action
Total Bank Loan Facilities Rated Rs.4000 Crore
Long Term Rating CRISIL AA+/Negative (Reaffirmed)
Short Term Rating CRISIL A1+ (Reaffirmed)
 
Rs.500 Crore Non Convertible Debentures CRISIL AA+/Negative (Reaffirmed)
Rs.1350 Crore Commercial Paper CRISIL A1+ (Reaffirmed)
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL has reaffirmed its ratings on the bank facilities and debt instruments of UPL Limited (UPL) at 'CRISIL AA+/Negative/CRISIL A1+'.

UPL's revenue registered a growth of 13% in fiscal 2020 driven by strong demand for agrochemicals in Latin America (LATAM, 34% of revenues), notwithstanding sub-par growth witnessed in Europe, Southeast Asia, and North America caused by uneven monsoon and pricing pressure. Operating profitability, though healthy, was nevertheless moderately lower  than expectations at ~20% on account of impact of purchase price allocation (PPA) on inventory acquired from Arysta, pricing pressures in US and Europe, as well as changes in  product mix in favour of lower margin products, which did well in LATAM markets.

The company's performance is expected to remain tepid in the first quarter of fiscal 2021 on account of ongoing concerns surrounding Covid-19, lockdowns and business in LATAM getting pushed closer to the sowing season (second and third quarter). Performance however, should pick up from second quarter onwards considering the essential nature of agricultural goods. Good monsoon in India and improving weather conditions in Europe should aid growth. CRISIL expects UPL to post moderate revenue growth of 7-9% and maintain operating profitability at 19-20% in fiscal 2021. Over the medium term, UPL is expected to sustain revenue growth of 8-10%, while its operating profitability is expected to improve to over 20%.

The company's net debt (~Rs.24000 crore at March 31, 2020) has reduced by ~Rs. 2200 crore backed by improvement in working capital management and part repayment of long term debt using proceeds from perpetual bonds of USD 400 Million in fiscal 2020. Hence, credit metrics such as interest cover and net debt / earnings before interest, tax, depreciation, and amortization (EBITDA) have improved, but remain moderate at 3.98 times and 3.39 times in fiscal 2020 (3.40 times and 6.52 times in fiscal 2019).

Credit metrics are expected to continue gradually improving as debt levels are further pruned, backed by steady demand prospects, healthy profitability, and sizeable cash generation, as well as moderated capital spending. UPL's ability to restore its credit metrics to levels commensurate with its rating category, will remain a monitorable. Also, given its current sizeable debt stock, UPL's ability to take on further material bolt-on large acquisitions may necessitate raising of equity at UPL or UPL Corp.
The ratings continue to reflect UPL's strong business risk profile supported by a strong market position, geographical diversification in revenue, and healthy profitability backed by sound operating efficiencies, leading to sizeable annual cash generation. Financial risk profile is expected to remain adequate and credit metrics improve gradually over the medium term, with increased integration benefits from the acquisition of Arysta. These strengths are partially offset by large working capital requirement and susceptibility to risks inherent in the agrochemical sector.

Analytical Approach

To arrive at its ratings, CRISIL has combined the business and financial risk profiles of UPL Ltd and its subsidiaries, collectively known as UPL. This is because all these companies are under a common management and have close operational linkages and fungible cash flows. CRISIL follows a moderate integration approach for investment in associates and joint ventures in which UPL has significant influence but not a controlling interest'specifically, CRISIL factors in UPL's share in the profit of these entities and any incremental investment required.

Goodwill on the acquisition of Arysta is being amortised over a period of 15 years commencing from fiscal 2019. Consequently, reported PAT, net worth, and ratio computations are adjusted.

USD denominated Perpetual Subordinated Capital Securities (Bonds) of USD 400 Million (interest coupon rate of 5.25% p.a.) raised by UPL Corporation Ltd (subsidiary of UPL) has been treated as 50% debt and 50% equity

Please refer Annexure - List of entities consolidated, which captures the list of entities considered and their analytical treatment of consolidation.

Key Rating Drivers & Detailed Description
Strengths: 
* Large scale with diverse geographical presence and wide product portfolio: UPL is among the top 5 players in the global agrochemicals industry by fiscal 2020. Revenue base is well diversified, with ~70% generated from Latin America, Europe, and the US in fiscal 2020. Wider geographical reach reduces susceptibility to cyclicality in demand from any one region. The company is also present across the crop lifecycle, from seeds, seed-treatment products, pre- and post-harvest products, to storage-treatment products. Business risk profile will remain healthy, aided by a combined portfolio of 12,400+ registrations, over 200 active ingredients, and 1,023 patents. The group is present in 138 countries with 48 manufacturing locations, employing more than 10,400 people across the globe.
 
* Sound operating efficiencies supporting healthy profitability: Backward integration and supply-chain management have strengthened operating efficiencies. As a sizeable portion of raw material and power requirement is met in-house, the group is assured a steady supply, with lesser price volatility. Flexible and multi-product manufacturing facilities, and the robust supply chain and distribution network have kept operating margin healthy at 17-20% over the five fiscals through March 2020. Profitability was impacted in the fourth quarter of fiscal 2019 and the first half of fiscal 2020 due to PPA adjustment on Arysta's inventory upon acquisition. Since this adjustment is non-recurring, profitability is not expected to be impacted adversely from fiscal 2021 onwards.

Synergistic cost savings of about USD 200 million are expected in fiscal 2021 on account of acquisition due to better backward integration, personnel and non-personnel cost savings, and various other geographical and logistical cost benefits. These benefits will also result in significant cost saving for the combined entity, leading to operating profitability of over 21% over the medium term, against 19.9% in fiscal 2020.
 
* Adequate financial risk profile: UPL's financial risk profile is adequate and supported by material annual operational cash flows and sizeable adjusted net worth of Rs 20, 570 crore estimated as on March 31, 2020. The acquisition of Arysta in fiscal 2019 was funded through substantial debt (~USD 3 billion), resulting in moderation in credit metrics. Interest coverage, net cash accrual to total debt and net debt to EBITDA ratios remained moderate at 3.98 times, 0.12 time and 3.39 time, respectively, in fiscal 2020.

UPL's management is, however, committed to reducing debt levels over the medium term. Along with strong operating performance and continuing healthy cash flow generating ability, net debt to EBITDA is expected to reduce to below 3.20 times in fiscal 2021 and below 2.70 times in fiscal 2022. Any additional material acquisition will remain a credit monitorable.
 
Weaknesses:
* Large working capital requirement: The crop protection business is seasonal in nature. Sales occur at the start of the season, but payment is realised post-harvest, resulting in long  receivable cycle. Furthermore, as goods are manufactured at one place and distributed to other locations, sizeable stock of finished goods needs to be maintained. The large credit required by customers in key Latin American markets also leads to a stretch in working capital cycle. However, the group will contain the exposure to markets with long credit cycle to less than one-third of its revenue and utilise securitisation benefits wherever available, thereby mitigating the impact of a stretched cycle on the overall credit profile. Also, UPL is expected to benefit from the smaller inventory of Arysta.
 
* Susceptibility to risks inherent in the agrochemicals sector: The crop-protection sector remains susceptible to specific and separate registration processes in different countries, and various environmental rules and regulations. Change in regulatory requirements, such as export and import policies and environmental and safety requirements in countries where the company has significant exposure, could weaken growth prospects. Furthermore, the sector is highly dependent on monsoon and level of farm income. Hence, timing and distribution of rainfall during a year plays a crucial role.
Liquidity Strong

Cash and cash equivalents stood at Rs 6750 crore as on March 31, 2020 (Rs 2,829 crore as on March 31, 2019). The company shored up liquidity by drawing down debt overseas, as a buffer to meet possible business requirements. Utilisation of domestic fund-based working capital limits was moderate at about 52% (of drawing power) for the 7 months through May 2020. While the company is expected to reduce its cash surpluses and pay down debt over a period of time, liquidity is still expected to remain strong over the medium term, supported by healthy cash generation (in excess of Rs.5000 crore annually), and notwithstanding large working capital requirements. Annual capital expenditure (capex) of about Rs 2,500 crore is also expected to be funded largely from internal accruals.

Outlook: Negative

UPL's business risk profile has improved with the acquisition of Arysta, propelling it to the position of the fifth-largest player in the global agrochemical space and the fourth-largest seed manufacturer. Better scale and business synergies are expected to also help improve operating profitability to over 20% over the medium term, benefitting cash generation. Albeit, financial risk profile, especially credit metrics, which were impacted by the sizeable acquisition-related debt are moderate at present, but expected to recover gradually over the medium term.

Rating Sensitivity factors
Upward factors
* Significant growth in revenue, with operating margin in excess of around 21%
* Net Debt/EBITDA reducing to below 3.20 times in fiscal 2021 and below 2.50-2.70 times in fiscal 2022 due to better-than-anticipated cash generation and lower debt level following prudent working capital or equity infusion.
 
Downward factors
* Significant decline in revenue and fall in operating profitability to below 17% in fiscals 2021 and 2022, thereby impacting cash generation
* Increase in net debt/EBITDA levels beyond 3.50 times in fiscal 2021 and above 3.00 times in fiscal 2022 due to lower cash generation or higher debt levels, due to large capex, working capital stretch or acquisitions
 
About UPL
Incorporated in 1969 and promoted by Mr Rajnikant Shroff, UPL manufactures, markets, and distributes crop protection products, intermediates, speciality chemicals, and other industrial chemicals; and undertakes research in these segments. Over time, UPL has made several acquisitions and entered into strategic alliances to diversify product profile and increase geographical reach. The group now includes over 200 entities. Apart from UPL, the other key operating companies in the group are United Phosphorus Inc (US), United Phosphorus Ltd (UK), Cerexagri SAS, Icona SA (Argentina), Decco US Post Harvest Inc, and UPL do Brasil Industria e Comercio de SA (Brazil). The company has manufacturing units in India, France, the Netherlands, Argentina, the UK, Vietnam, Turkey, Brazil, the USA, China, Thailand, Italy, Australia, and Columbia.

Promoters hold 27.9% stake in UPL Ltd, while foreign institutional investors hold 43.5%, mutual funds 4.1% and other public the balance.

About Arysta
Arysta is an agrochemical company with almost the entire production process outsourced to third parties in various geographies such as China, Eastern Europe, and India. Arysta owns about 800 domestic and foreign patents, and approximately 6,800 product registrations. It specialises in the development, formulation, registration, marketing, and distribution of differentiated crop protection solutions, including BioSolutions and Seed treatments, for a variety of crops and applications. The company has presence in over 100 countries globally.
Key Financial Indicators
Particulars for year ending March 31 Unit 2020 2019 2018
Revenue Rs crore 35,756 21,799 17,378
Adjusted profit after tax (PAT)^ Rs crore 1,064 1,352 2,030
PAT margin^ % 3.0 6.2 11.7
Adjusted debt/Adjusted net worth^ Times 1.50 1.68 0.84
 Adjusted interest coverage Times 3.98 3.40 4.90
^CRISIL-adjusted numbers for treatment of goodwill

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments and are included (where applicable) in the Annexure -- Details of Instrument in this Rating Rationale. For more details on the CRISIL complexity levels, please visit www.crisil.com/complexity-levels.
Annexure - Details of Instrument(s)
ISIN Name of instrument Date of allotment Coupon
rate (%)
Maturity date Issue size
(Rs crore)
Complexity level Rating assigned  with outlook
N.A. Non-Convertible Debentures* N.A. N.A. N.A. 500 Simple CRISIL AA+/Negative
N.A. Cash Credit## N.A. N.A. N.A. 1150 NA CRISIL AA+/Negative
N.A. Letter of credit & Bank Guarantee N.A. N.A. N.A. 650 NA CRISIL A1+
N.A Proposed Cash Credit Limit N.A. N.A. N.A. 500 NA CRISIL AA+/Negative
N.A. Proposed Working Capital Facility** N.A. N.A. N.A. 1500 NA CRISIL AA+/Negative
N.A. Proposed Long Term Bank Loan Facility** N.A. N.A. N.A. 200 NA CRISIL AA+/Negative
N.A. Commercial Paper N.A. N.A. 7-365 days 1350 Simple CRISIL A1+
*Yet to be issued
##Fully interchangeable between cash credit, working capital demand loan, foreign currency non-resident (Bank) loans, packing credit in INR, packing credit in foreign currency, export bill discounting in INR and foreign currency, buyer's credit for imports and domestic purchases, and domestic sales bill discounting. It can also be converted into non-fund-based facilities.
**It can be converted into non-fund-based facilities.
 
Annexure - List of entities consolidated
Sr.No Fully consolidated entities Extent of Consolidation Rationale
1 Shroffs United Chemicals  Ltd Full Wholly owned subsidiary
2 SWAL Corporation Ltd Full Wholly owned subsidiary
3 United Phosphorus  (India)  LLP Full Wholly owned subsidiary
4 United Phosphorus  Global LLP Full Wholly owned subsidiary
5 Optima Farm Solutions  Ltd Full Wholly owned subsidiary
6 UPL Europe  Ltd Full Wholly owned subsidiary
7 UPL Deutschland GmbH Full Wholly owned subsidiary
8 United Phosphorus  Polska  Sp.z o.o Full Wholly owned subsidiary
9 UPL Benelux  B.V. Full Wholly owned subsidiary
10 Cerexagri  B. V. Full Wholly owned subsidiary
11 United Phosphorus  Holdings  Cooperatief U.A. Full Wholly owned subsidiary
12 United Phosphorus  Holdings  B.V Full Wholly owned subsidiary
13 Decca  Worldwide  Post-Harvest Holdings Cooperatief U.A. Full Step down subsidiary
14 Decca  Worldwide  Post-Harvest Holdings B.V. Full Step down subsidiary
15 United Phosphorus Holding,  Brazil B.V UPL Full Wholly owned subsidiary
16 Italia S.R.L Full Wholly owned subsidiary
17 UPL Iberia,  S.A Full Wholly owned subsidiary
18 Decca  lberica  Postcosecha,  S.A.U. Full Step down subsidiary
19 Transterra  Invest,  S. L. U. Full Wholly owned subsidiary
20 Cerexagri  S.A. S. Full Wholly owned subsidiary
21 Neo-Fog  S.A. Full Wholly owned subsidiary
22 UPL France Full Wholly owned subsidiary
23 United Phosphorus Switzerland Ltd. Full Wholly owned subsidiary
24 Agrodan,  ApS Full Wholly owned subsidiary
25 Decca  Italia SRL Full Wholly owned subsidiary
26 Ltd Liability Company  "UPL" Full Wholly owned subsidiary
27 Decca Portugal  Post Harvest LOA Full Wholly owned subsidiary
28 UPL NA Inc.  (formerly known as United Phosphorus  Inc.) Full Wholly owned subsidiary
29 UPI Finance  LLC Full Wholly owned subsidiary
30 Cerexagri,  Inc. (PA) Full Wholly owned subsidiary
31 UPL Delaware, Inc. Full Wholly owned subsidiary
32 Canegrass  LLC Full Wholly owned subsidiary
33 Decca  US Post-Harvest Inc. Full Step down subsidiary
34 Essentiv  LCC Full Wholly owned subsidiary
35 RiceCo  LLC Full Wholly owned subsidiary
36 Riceco International,  Inc. Full Wholly owned subsidiary
37 UPL Corporation Ltd Full Wholly owned subsidiary
38 UPL Management DMCC Full Wholly owned subsidiary
39 UPL Ltd, Gibraltar Full Wholly owned subsidiary
40 UPL Agro  SA DE CV. Full Wholly owned subsidiary
41 Decco PostHarvest Mexico Full Wholly owned subsidiary
42 Perrey Participacoes  S.A Full Wholly owned subsidiary
43 Uniphos  Industria e Comercio  de Produtos Quimicos  Ltda. Full Wholly owned subsidiary
44 UPL Do Brasil - Industria e Comercio  de Insumos Agropecuarios  S.A. Full Wholly owned subsidiary
45 UPL Costa Rica S.A. Full Wholly owned subsidiary
46 UP Bolivia S.R.L Full Wholly owned subsidiary
47 UPL Paraguay S.A. Full Wholly owned subsidiary
48 Icona Sanluis S.A Full Wholly owned subsidiary
49 UPL Argentina S.A. Full Wholly owned subsidiary
50 Decco Chile SpA Full Wholly owned subsidiary
51 UPL Colombia  SAS Full Wholly owned subsidiary
52 United Phosphorus Cayman Ltd Full Wholly owned subsidiary
53 UP Aviation Ltd Full Wholly owned subsidiary
54 UPL Australia Ltd Full Wholly owned subsidiary
55 UPL New Zealand Ltd Full Wholly owned subsidiary
56 UPL Shanghai  Ltd Full Wholly owned subsidiary
57 UPL Ltd Korea  Co., Ltd Full Wholly owned subsidiary
58 PT.UPL Indonesia Full Wholly owned subsidiary
59 PT Catur Agrodaya  Mandiri Full Wholly owned subsidiary
60 UPL Ltd, Hong Kong Full Wholly owned subsidiary
61 UPL Philippines Inc. Full Wholly owned subsidiary
62 UPL Vietnam Co.  Ltd Full Wholly owned subsidiary
63 UPL Ltd,  Japan Full Wholly owned subsidiary
64 Anning  Decco  Fine Chemical  Co. Ltd Full Wholly owned subsidiary
65 UPL Ziraat Ve Kimya  Sanayi Ve Ticaret Ltd Sirketi Full Wholly owned subsidiary
66 UPL Agromed  Tohumculuk SA Full Wholly owned subsidiary
67 Safepack Products  Ltd Citrashine (Pty) Ltd Full Wholly owned subsidiary
68 Prolong  Ltd Full Wholly owned subsidiary
69 Agrinet  Solutions  Ltd Full Wholly owned subsidiary
70 Advanta  Holdings  B.V. Full Step down subsidiary
71 Advanta Netherlands  Holdings  B.V. Full Step down subsidiary
72 Advanta  US LLC Full Wholly owned subsidiary
73 Advanta  Seeds International Full Wholly owned subsidiary
74 Advanta  Seeds DMCC Full Step down subsidiary
75 Advanta  Commercio De Sementes LTDA Full Step down subsidiary
76 Advanta Semillas  SAIC Full Step down subsidiary
77 Advanta  Seeds Pty Ltd Full Step down subsidiary
78 Pacific  Seeds  (Thai) Ltd Full Wholly owned subsidiary
79 Pacific  Seeds Holdings  (Thai) Ltd Full Wholly owned subsidiary
80 PT Advanta  Seeds Indonesia Full Step down subsidiary
81 Advanta  Seeds Ukraine LLC Full Wholly owned subsidiary
82 UPL Jiangsu  Ltd Full Wholly owned subsidiary
83 UPL Ltd (formerly known as UPL Agro Ltd) Full Wholly owned subsidiary
84 Riceco International  Bangladesh Ltd Full Wholly owned subsidiary
85 Uniphos Malaysia Sdn Bhd Full Wholly owned subsidiary
86 Decco Gida  Tanm  ve Zirai  Urimler San. Tic A.S Full Wholly owned subsidiary
87 Arysta LifeScience Investments LLC Full Wholly owned subsidiary
88 Arysta LifeScience America Inc. ANESA  S.A. Full Wholly owned subsidiary
89 Arysta LifeScience Management Company,  LLC, USA Full Wholly owned subsidiary
90 Arysta LifeScience  SPC, LLC, USA Arysta LifeScience India Ltd, India Full Wholly owned subsidiary
91 Arysta LifeScience Agriservice  Private Ltd,  India Full Wholly owned subsidiary
92 Arysta LifeScience Togo SAU, Togo Full Wholly owned subsidiary
93 Arysta Agro  Private Ltd,  India Full Wholly owned subsidiary
94 Arysta LifeScience do Brasil Industria Quimica  e Agropecuaria SA, Brasil Full Wholly owned subsidiary
95 Volcano  Agrociencia Industria e Comercio  de Defensivos Agricolas  Ltda,  Brasil Full Wholly owned subsidiary
96 GBM USA LLC, USA Full Wholly owned subsidiary
97 Arysta LifeScience Canada, Inc.,  Canada Full Step down subsidiary
98 Arysta LifeScience Canada BC Inc., Canada Full Step down subsidiary
99 Arysta LifeScience North America,  LLC, USA Full Step down subsidiary
100 Arysta LifeScience NA Holding LLC, USA Full Step down subsidiary
101 Arysta LifeScience Inc, USA Full Wholly owned subsidiary
102 Arysta LifeScience Services LLP, India Full Step down subsidiary
103 Arysta LifeScience France SAS, France Full Step down subsidiary
104 Arysta  LifeScience Benelux  SPRL,  Belgium Full Step down subsidiary
105 Arysta LifeScience (Mauritius)  Ltd, Mauritius Full Step down subsidiary
106 Arysta LifeScience South Africa (Pty) Ltd, South Africa Full Step down subsidiary
107 Arysta Health and Nutrition Sciences Corporation,  Japan Full Step down subsidiary
108 Arysta LifeScience Corporation, Japan Full Step down subsidiary
109 Arysta LifeScience  S.A.S.,  France Full Step down subsidiary
110 Arysta LifeScience Chile S.A.  Chile Full Step down subsidiary
111 Arysta LifeScience Mexico,  S.A.de C.V, Mexico Full Step down subsidiary
112 Grupo Bioquimico Mexicano,  S.A.  de C.V. Mexico Full Wholly owned subsidiary
113 MacDermid Agricultural  Solutions Netherlands  Cooperatief UA, Netherlands Full Wholly owned subsidiary
114 Arysta LifeScience UK & Ireland Ltd, UK Full Step down subsidiary
115 Arysta LifeScience  Europe Sarl,  Europe Full Step down subsidiary
116 MacDermid Agricultural  Solutions  Italy Srl, Netherlands Full Wholly owned subsidiary
117 Dutch Agricultural  Investment  Partners LLC, USA Full Wholly owned subsidiary
118 Netherlands Agricultural  Investment Partners LLC, USA Full Wholly owned subsidiary
119 Arysta LifeScience Bulgaria EOOD, Bulgaria Full Step down subsidiary
120 Arysta LifeScience Romania  SRL, Romania Full Step down subsidiary
121 Arysta LifeScience Kiev LLC, Ukraine Full Step down subsidiary
122 Arysta LifeScience Great Britain Ltd, UK Full Step down subsidiary
123 Arysta LifeScience Technology  BY, Netherlands Full Step down subsidiary
124 Arysta LifeScience Netherlands BY, Netherlands Full Step down subsidiary
125 Arysta LifeScience RUS LLC, Russia Full Step down subsidiary
126 Netherlands Agricultural Technologies  CV, Netherlands Full Wholly owned subsidiary
127 Dutch Agricultural  Formations  CV, Netherlands Full Wholly owned subsidiary
128 Arysta LifeScience Turkey Tarim Urunleri  Ltd  Sirketi, Turkey Full Step down subsidiary
129 Arysta  LifeScience Australia Pty Ltd., Australia Full Step down subsidiary
130 Chemtura  (Thailand) Ltd, Thailand Full Wholly owned subsidiary
131 MacDermid (Shanghai) Chemical  Ltd., China Full Wholly owned subsidiary
132 Arysta-LifeScience Ecuador S.A.Ecuador Full Wholly owned subsidiary
133 Arysta LifeScience Ougree Production Sprl, Belgium Full Wholly owned subsidiary
134 Arysta LifeScience Hellas S.A.  Plant Protection,  Nutrition and Other Related Products  and Services,Greece Full Wholly owned subsidiary
135 Arysta LifeScience Iberia SLU, Spain Full Wholly owned subsidiary
136 Arysta Lifescience Italia SrL, Italy Full Wholly owned subsidiary
137 Agriphar Poland Sp. Zoo, Poland Full Wholly owned subsidiary
138 Arysta  LifeScience  Switzerland  Sarl, Switzerland Full Wholly owned subsidiary
139 Arysta Animal  Health SAS, France Full Wholly owned subsidiary
140 PPWJ  Sci,  France Full Wholly owned subsidiary
141 Santamix  lberica  SL, Spain Full Wholly owned subsidiary
142 Arysta LifeScience Global Services  Ltd, Full Wholly owned subsidiary
143 Ireland Arysta LifeScience European  Investments Ltd, UK Full Wholly owned subsidiary
144 Arysta LifeScience U.K. Ltd,  UK Full Step down subsidiary
145 Arysta LifeScience U.K.  CAD Ltd, UK Full Step down subsidiary
146 Arysta LifeScience U.K. EUR Ltd, UK Full Step down subsidiary
147 Arysta LifeScience U.K.  JPY Ltd, UK Full Step down subsidiary
148 Arysta LifeScience U.K.  USD Ltd, UK Full Step down subsidiary
149 Arysta Lifescience U.K.  Holdings  Ltd,  UK Full Step down subsidiary
150 Arysta LifeScience Japan Holdings  Goudou  Kaisha, Japan Full Wholly owned subsidiary
151 Arysta LifeScience Cameroun  SA, Cameroun Full Step down subsidiary
152 Callivoire SGFD S.A.,  COTE D'IVOIRE Full Wholly owned subsidiary
153 Arysta LifeScience Egypt Ltd, Egypt Full Wholly owned subsidiary
154 Calli  Ghana Ltd., Ghana Full Wholly owned subsidiary
155 Arysta  LifeScience Kenya Ltd., Kenya Full Step down subsidiary
156 Mali Protection Des Cultures (M.P.C.)  SA, Mali Full Wholly owned subsidiary
157 Agrifocus Limitada,  Mozamnique Full Step down subsidiary
158 Arysta LifeScience Holdings  SA (Pty) Ltd, South Africa Full Wholly owned subsidiary
159 Anchorprops 39  (Pty) Ltd, South Africa Full Wholly owned subsidiary
160 Callietha Investments (Pty) Ltd, South Africa Full Wholly owned subsidiary
161 Sidewalk Trading  (Pty) Ltd, South Africa Full Wholly owned subsidiary
162 Volcano Agroscience (Pty) Ltd, South Africa Full Wholly owned subsidiary
163 Volcano Chemicals (Pty) Ltd, South Africa Full Wholly owned subsidiary
164 Arysta LifeScience Tanzania  Ltd, Tanzania Full Step down subsidiary
165 Arysta LifeScience (Shanghai) Co., Ltd., China Full Step down subsidiary
166 Pt.  Arysta LifeScience Tirta Indonesia,  Indonesia Full Step down subsidiary
167 Arysta LifeScience Korea Ltd, Korea Full Step down subsidiary
168 Arysta LifeScience Pakistan (Pvt.) Ltd., Pakistan Full Step down subsidiary
169 Arysta LifeScience Philippines  Inc.,  Phillipines Full Step down subsidiary
170 Arysta  LifeScience Asia Pte., Ltd., Singapore Full Step down subsidiary
171 Arysta LifeScience (Thailand) Co., Ltd., Thailand Full Step down subsidiary
172 Arysta LifeScience Vietnam  Co., Ltd., Vietnam Full Step down subsidiary
173 Arysta LifeScience Holdings  France SAS, France Full Step down subsidiary
174 Goernar Developpernent SAS, France Full Wholly owned subsidiary
175 Laboratoires Goernar  SAS, France Full Wholly owned subsidiary
176 Natural  Plant Protection  S.A.S., France Full Wholly owned subsidiary
177 Arysta LifeScience Czech s.r.o., Czech Republic Full Step down subsidiary
178 Arysta LifeScience Germany  GmbH, Germany Full Step down subsidiary
179 Arysta LifeScience Magyarorszag Kft., Hungary Full Step down subsidiary
180 Arysta LifeScience Polska Sp. z.o.o,  Poland Full Step down subsidiary
181 Arysta  LifeScience Vostok Ltd., Russia Full Step down subsidiary
182 Betel Reunion  S.A.,Reunion Full Step down subsidiary
183 Arysta LifeScience Slovakia S.R.O.,  Slovakia Full Step down subsidiary
184 Arysta LifeScience Ukraine  LLC; Ukraine Full Step down subsidiary
185 Arysta LifeScience Global  Ltd,  UK Full Step down subsidiary
186 Arysta LifeScience Argentina S.A., Argentina Full Step down subsidiary
187 Arysta LifeScience Colombia  S.A.S, Colombia Full Step down subsidiary
188 Arysta LifeScience Centro America,  S.A.,  Guatemala Full Step down subsidiary
189 Arysta LifeScience Mexico  Holding S.A.de C.V, Mexico Full Step down subsidiary
190 Bioenzymas  S.A.  de C.V.,  Mexico Full Wholly owned subsidiary
191 Desarrollos  Inmobiliarios Alianza de Coahuila,  S.A.  de C.V.,  Mexico Full Wholly owned subsidiary
192 Omega Agroindustrial,  S.A. de C.V., Mexico Full Wholly owned subsidiary
193 Agroquimicos y Semillas,  S.A.  de C.V., Mexico Full Wholly owned subsidiary
194 Servicios  Agricolas  Mundiales  SA de CV, Mexico Full Wholly owned subsidiary
195 Tecno Extractos Vegetales,  S.A.  de C.V., Mexico Full Wholly owned subsidiary
196 Tesaurus  Mexico  S.A. de C.V.,  Mexico Full Wholly owned subsidiary
197 Arysta LifeScience Paraguay  S.R.L., Paraguay Full Step down subsidiary
198 Arysta LifeScience Peru S.A.C, Peru Full Step down subsidiary
199 Arysta  LifeScience Costa Rica SA., Costa Rica Full Step down subsidiary
200 Arysta LifeScience de Guatemala,  S.A., Guatemala Full Step down subsidiary
201 Arysta  LifeScience  S.R.L.,Bolivia Full Step down subsidiary
202 Myanmar  Arysta LifeScience Co., Ltd., Myanmar Full Step down subsidiary
203 Arysta LifeScience U.K.  BRL Ltd,  UK Full Step down subsidiary
204 Etec Crop Solutions Ltd, New Zealand Full Wholly owned subsidiary
205 MacDermid  Agricultural  Solutions Australia  Pty Ltd, Australia Full Wholly owned subsidiary
206 Arvesta  Corporation,  USA Full Step down subsidiary
207 Arysta LifeScience Registrations Great Britain Ltd, UK Full Step down subsidiary
208 Agriphar  SDN BHD, Malaysia Full Wholly owned subsidiary
209 Agriphar  de Costa Rica SA, Costa Rica Full Wholly owned subsidiary
210 Agriphar  de Colombia SAS; Colombia Full Wholly owned subsidiary
211 Industrias Agriphar  SA, Guatemala Full Wholly owned subsidiary
212 Kempton  Chemicals  (Pty) Ltd, South Africa Full Wholly owned subsidiary
213 Agripraza  Ltda.,  Portugal Full Wholly owned subsidiary
214 Arysta LifeScience Corporation  Republica Dominicana,  SRL, Dominican Republic Full Step down subsidiary
215 Grupo Bioquimico  Mexicano  Republica  Dominicana  SA, Dominican  Republic Full Step down subsidiary
216 Arysta LifeScience Ecuador  S.A., Ecuador Full Step down subsidiary
217 Arvesta  Paraguay  S.A., Paraguay Full Step down subsidiary
218 Arysta Agroquimicos y Fertilzantes  Uruguay SA, Uruguay Full Step down subsidiary
219 Arysta LifeScience U.K.  USD-2 Ltd,  UK Full Step down subsidiary
220 MacDermid Agricultural  Solutions  Holdings BV Full Step down subsidiary
Annexure - Rating History for last 3 Years
  Current 2020 (History) 2019  2018  2017  Start of 2017
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Commercial Paper  ST  1350.00  CRISIL A1+      30-12-19  CRISIL A1+  22-10-18  CRISIL A1+  17-10-17  CRISIL A1+  CRISIL A1+ 
            09-09-19  CRISIL A1+  24-07-18  CRISIL A1+  31-08-17  CRISIL A1+   
            02-01-19  CRISIL A1+           
Non Convertible Debentures  LT  0.00
10-07-20 
CRISIL AA+/Negative      30-12-19  CRISIL AA+/Negative  22-10-18  CRISIL AA+/Watch Negative  17-10-17  CRISIL AA+/Stable  -- 
            09-09-19  CRISIL AA+/Negative  24-07-18  CRISIL AA+/Watch Negative       
            02-01-19  CRISIL AA+/Negative           
Fund-based Bank Facilities  LT/ST  3350.00  CRISIL AA+/Negative      30-12-19  CRISIL AA+/Negative  22-10-18  CRISIL AA+/Watch Negative  17-10-17  CRISIL AA+/Stable  CRISIL AA+/Stable 
            09-09-19  CRISIL AA+/Negative  24-07-18  CRISIL AA+/Watch Negative  31-08-17  CRISIL AA+/Stable   
            02-01-19  CRISIL AA+/Negative           
Non Fund-based Bank Facilities  LT/ST  650.00  CRISIL A1+      30-12-19  CRISIL A1+  22-10-18  CRISIL A1+  17-10-17  CRISIL A1+  CRISIL A1+ 
            09-09-19  CRISIL A1+  24-07-18  CRISIL A1+  31-08-17  CRISIL A1+   
            02-01-19  CRISIL A1+           
All amounts are in Rs.Cr.
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Cash Credit## 1150 CRISIL AA+/Negative Cash Credit## 1150 CRISIL AA+/Negative
Letter of credit & Bank Guarantee 650 CRISIL A1+ Letter of credit & Bank Guarantee 650 CRISIL A1+
Proposed Cash Credit Limit 500 CRISIL AA+/Negative Proposed Cash Credit Limit 500 CRISIL AA+/Negative
Proposed Long Term Bank Loan Facility** 200 CRISIL AA+/Negative Proposed Long Term Bank Loan Facility** 200 CRISIL AA+/Negative
Proposed Working Capital Facility** 1500 CRISIL AA+/Negative Proposed Working Capital Facility** 1500 CRISIL AA+/Negative
Total 4000 -- Total 4000 --
##Fully interchangeable between cash credit, working capital demand loan, foreign currency non-resident (Bank) loans, packing credit in INR, packing credit in foreign currency, export bill discounting in INR and foreign currency, buyer's credit for imports and domestic purchases, and domestic sales bill discounting. It can also be converted into non-fund-based facilities.
**It can be converted into non-fund-based facilities.
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating criteria for manufaturing and service sector companies
Rating Criteria for Chemical Industry
CRISILs Criteria for Consolidation
CRISILs Criteria for rating short term debt

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Anuj Sethi
Senior Director - CRISIL Ratings
CRISIL Limited
B:+91 44 6656 3100
anuj.sethi@crisil.com


Sameer Charania
Director - CRISIL Ratings
CRISIL Limited
D:+91 22 4097 8025
sameer.charania@crisil.com


Biswa Sukla
Rating Analyst - CRISIL Ratings
CRISIL Limited
D:+91 44 6656 3137
Biswa.Sukla@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.CRISIL or its associates may have other commercial transactions with the company/entity.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL